HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NAD zeroes in on cosmetics ads

This article was originally published in The Rose Sheet

Executive Summary

The National Advertising Division is paying increasing attention to cosmetics firms' ads, according to David Mallen, assistant director for legal affairs at the Council of Better Business Bureau unit. "It's an area where we've been very involved lately. We expect to be more involved," he remarked May 1 at an advertising law conference sponsored by the American Conference Institute and held in Washington, D.C. He referenced an industry task force developing standards for organic personal-care products that will help firms develop effective advertising using claims that neither unfairly or inaccurately compare their products with competitors' nor make misleading representations to consumers (1"The Rose Sheet" Jan. 29, 2007, p. 5)...

You may also be interested in...



Task Force To Release Standards For Organic Personal Care Products In 2007

A task force of industry reps and consumer advocates will release the first draft of standards for organic personal care products by mid-2007, insiders say

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014715

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel